A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Rifapentine (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
Indications Pulmonary tuberculosis
Focus Adverse reactions; Therapeutic Use

28 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
03 Jun 2014 Planned end date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
05 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com